Key Highlights

  • BPH Energy(ASX:BPH) reported investee Advent Energy has appealed the PEP 11 Federal Court judgment to the Full Court
  • Cortical Dynamics' BARM 2.0 brain and pain monitoring MVP is nearing technical completion ahead of planned US and Netherlands clinical trials
  • Clean Hydrogen Technologies has signed a Letter of Intent with Horizon Fuel Cells for clean hydrogen Supply to US data centres
  • BPH holds a 35.8% direct interest in Advent Energy, 16.4% in Cortical Dynamics, and 16.1% in Clean Hydrogen Technologies

BPH Energy Limited(ASX:BPH) provided updates on its three principal investees during the September 2026 quarter, with developments spanning offshore gas exploration, medical devices and clean hydrogen technology.

The investment-focused company holds direct interests in Advent Energy Limited (35.8%), Cortical Dynamics Limited (16.4%) and Clean Hydrogen Technologies (16.1%).

What Is the Status of PEP 11?

Advent Energy's Subsidiary Asset Energy is a participant in the PEP 11 Joint Venture with Bounty Oil and Gas NL (ASX:BUY), holding an 85% participating interest. The Joint Authority's refusal of the PEP 11 extension and variation applications remains in place, and Advent has appealed the judgment of Justice Jackson, delivered on 17 June 2026, to the Full Court of the Federal Court of Australia. Senior Counsel has been engaged for the appeal.

Separately, in March 2025 Advent applied to NOPTA for renewal of the PEP11 permit over 50% of the existing permit area. That application remains under consideration.

Advent's onshore subsidiary Onshore Energy entered voluntary administration in April 2026, with its primary asset being Retention Licence RL1 containing the Weaber Gas Field in the Northern Territory.

What Is Cortical Dynamics' Progress?

Cortical Dynamics' next-generation BARM 2.0 brain and pain monitoring minimum viable product is nearing technical completion. Post completion, the device will undergo EMC testing (electrical safety) and biocompatibility and shelf-life testing for BarSensors. Clinical Trials are scheduled in the USA and the Netherlands, followed by regulatory submissions worldwide.

BARM 2.0 is described as the only solution that unifies hypnotic depth and pain response monitoring, combining EEG with AI in one system. The addressable market covers more than 300 million operations globally per annum under general anaesthesia.

What About Clean Hydrogen Technologies?

CHT has demonstrated consistent production of turquoise hydrogen and CNT composite at its pilot plant in Nashik, India. The company has signed a Letter of Intent with Horizon Fuel Cells to supply clean hydrogen for data centres in the USA. CHT is pursuing a proposed Nasdaq listing via a SPAC.